The pharmacological pillars of the last two chapters do most of the heavy lifting in slowing CKD, but they do not act in a vacuum. What the patient eats and how they live can blunt those drugs or amplify them, and the same final common pathway that the pillars target is fed by dietary protein, sodium, and obesity. This chapter closes Part 2 by adding the non-pharmacological layer — lowering proteinuria as an explicit goal, moderating protein and sodium, navigating potassium sensibly, and addressing weight, smoking, and activity — all while never tipping a CKD patient into malnutrition.
Proteinuria as the target
Chapter 2 established that proteinuria is a mediator of progression, not merely a marker, and Chapters 4 and 5 showed that the pillars lower it. The unifying clinical idea is that proteinuria is a target: the degree to which it is reduced tracks the renoprotection achieved, so albuminuria is measured repeatedly to titrate therapy, much as HbA1c is in diabetes. Diet and lifestyle are part of how that target is reached. Sodium restriction and weight loss lower proteinuria directly, and they magnify the antiproteinuric effect of the drugs, so the non-pharmacological measures are not a token addition but a genuine lever on the same endpoint the whole volume cares about.
Dietary protein: moderate, never starving
A high protein load causes the afferent arteriole to dilate, raising single-nephron filtration and glomerular pressure — the hyperfiltration engine of Chapter 2 driven by the dinner plate. Moderating protein intake reduces that hyperfiltration and lowers proteinuria, which is why a moderate intake of around 0.8 g/kg/day is advised in non-dialysis CKD, a high-protein intake is discouraged, and very-low-protein diets are reserved for supervised use with keto-analogue supplementation. But the crucial counterweight is malnutrition. Protein-energy wasting is common in CKD and independently worsens outcomes, and overzealous protein restriction is a fast route into it. So the instruction is moderate, not minimal, with adequate energy intake, regular nutritional assessment, and a dietitian closely involved — and the principle reverses entirely once a patient starts dialysis, when protein needs rise. The art is to relieve the hyperfiltration without starving the patient.
Sodium: the key that unlocks the pillars
Sodium restriction is one of the highest-yield dietary measures, and its value is as much pharmacological as direct. A high-sodium diet expands volume, raises blood pressure, and — importantly — blunts the antiproteinuric and antihypertensive effect of RAAS blockade and SGLT2 inhibition, so a patient eating a lot of salt gets less from the very drugs meant to protect them. Restricting sodium to below about 2 g daily, roughly 5 g of salt, lowers blood pressure and proteinuria in its own right and unlocks the full effect of the pillars. The synergy is real and underused: a resistant proteinuria on maximal RAAS blockade is often a high-salt diet in disguise, and addressing the sodium can achieve what another drug would not.
The potassium paradox
Potassium creates a genuine dilemma. The diet that is best for CKD and the cardiovascular system — rich in fruit, vegetables, and legumes — is potassium-rich, yet the pillars that protect the kidney, RAAS blockade and finerenone, raise serum potassium. The old reflex was to restrict potassium broadly, which pushed patients toward a processed, plant-poor diet that harmed them in other ways. The modern resolution is to individualise. Potassium in plant foods is less bioavailable than the inorganic potassium of additives, so a plant-rich diet raises serum potassium less than its content suggests; SGLT2 inhibitors lower potassium and help offset the pillars; and potassium binders can be used specifically to permit a healthy diet and the protective drugs together. Blanket potassium restriction is reserved for genuine, persistent hyperkalaemia — not applied pre-emptively at the cost of an otherwise beneficial diet.
Weight, and the obese kidney
Obesity is a renal risk factor in its own right, partly because it drives hyperfiltration: the increased metabolic demand of excess body mass raises single-nephron filtration and glomerular pressure, producing an obesity-related glomerulopathy with proteinuria. The corollary is therapeutic — weight loss reduces hyperfiltration and proteinuria. Lifestyle measures, the GLP-1 receptor agonists of Chapter 5 with their weight and kidney benefit, and bariatric surgery in appropriate patients all lower weight and, with it, the hyperfiltration burden. Addressing obesity is therefore not a generic health recommendation bolted onto CKD care but a direct intervention on the same mechanism the pillars target.
Smoking, activity, and the rest of the bundle
Several further lifestyle measures earn their place. Smoking accelerates both CKD progression and the cardiovascular disease that kills most CKD patients, so cessation is a renoprotective act, not merely general advice. Regular physical activity reduces cardiovascular risk and frailty, the latter especially relevant as CKD advances. Alcohol is moderated. And nephrotoxin avoidance — NSAIDs above all — recurs here as it has throughout both volumes, because a single avoidable insult can undo months of careful progression-slowing. Glycaemic control in diabetes belongs to this bundle too, developed fully in the diabetic kidney disease chapter. None of these is dramatic alone, but together they form the lifestyle scaffold around the pharmacological pillars.
Putting it together with the dietitian
The non-pharmacological measures work best as a coordinated plan rather than a list of prohibitions, and the dietitian is central to delivering it. The plan moderates protein without courting malnutrition, restricts sodium to unlock the pillars, individualises potassium to permit a healthy diet, drives weight loss where obesity contributes, and folds in smoking cessation, activity, and nephrotoxin avoidance. It is delivered alongside the drugs, not as an alternative to them, and it is monitored by the same target — albuminuria — that tracks the whole strategy. Done well, diet and lifestyle are not the soft adjunct to 'real' treatment but a measurable, mechanistically grounded part of slowing progression.
Where the evidence is firm, and where it is softer
The firm parts are the synergistic ones: that sodium restriction augments RAAS-blockade renoprotection, that weight loss reduces proteinuria, and that smoking accelerates progression are well supported. The protein story is genuinely softer — the landmark dietary-protein trial was inconclusive, and meta-analyses suggest only a modest benefit from restriction, weighed against a real malnutrition risk — so the recommendation is moderate and individualised rather than aggressive. The plant-dominant-diet evidence is promising but still maturing. The honest position is to deploy the high-yield, well-supported measures — sodium, weight, smoking, nephrotoxin avoidance — confidently, to moderate protein without dogmatism, and to let a dietitian and the albuminuria response guide the individual, never sacrificing nutrition for a theoretical gain.
